Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists
1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado Subm...
Gespeichert in:
Veröffentlicht in: | American journal of physiology. Heart and circulatory physiology 2008-04, Vol.294 (4), p.H1685-H1692 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | H1692 |
---|---|
container_issue | 4 |
container_start_page | H1685 |
container_title | American journal of physiology. Heart and circulatory physiology |
container_volume | 294 |
creator | Van Guilder, Gary P Stauffer, Brian L Greiner, Jared J DeSouza, Christopher A |
description | 1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado
Submitted 1 November 2007
; accepted in final form 13 February 2008
Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO.
cell surface receptors; intracellular signaling pathways; nitric oxide
Address for reprint requests and other correspondenc |
doi_str_mv | 10.1152/ajpheart.01281.2007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_highw</sourceid><recordid>TN_cdi_highwire_physiology_ajpheart_294_4_H1685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1460409201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</originalsourceid><addsrcrecordid>eNp1UV2LEzEUDaK4dfUXCBJ8n24-JukMgiCL6y4s-LI-h3Ry00mZScYk07VP_nVTW-v64FMI5-Oeew9CbylZUirYld5OPeiYl4Syhi4ZIatnaFEQVlHB2-doQbjklaRcXKBXKW0JIWIl-Ut0QZui4Kt2gX7ejZN2EQwGb0LuYXDzWBmYyhd8xjudgnGDzi547DwOO4iP4DZ9xtobHNaQAGszDxn386h9wi5hHzIe3Ohysc0Bj3PqdHTedThCB1MOEetN8C7l9Bq9sHpI8Ob0XqJvN58frm-r-69f7q4_3Vdd2SdXYCwzFARIsK22TddoyVZMMGE7a0hTkHotCLcW6q5uNDGSWIBG0rWw0lB-iT4efad5PYLpym5RD2qKbtRxr4J26l_Eu15twk5xWUxoXQzenwxi-D5Dymob5uhLZsVYK0UryGEKP5K6GFKKYM8DKFGH0tSf0tTv0tShtKJ69zTbX82ppUL4cCT05fCPpS019fvkwhA2e3UzD8MD_Mhna9bWqla3VDZCTcYW9dX_1ec8T1T8F4n6wV4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>229659501</pqid></control><display><type>article</type><title>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</title><source>MEDLINE</source><source>American Physiological Society</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Van Guilder, Gary P ; Stauffer, Brian L ; Greiner, Jared J ; DeSouza, Christopher A</creator><creatorcontrib>Van Guilder, Gary P ; Stauffer, Brian L ; Greiner, Jared J ; DeSouza, Christopher A</creatorcontrib><description>1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado
Submitted 1 November 2007
; accepted in final form 13 February 2008
Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO.
cell surface receptors; intracellular signaling pathways; nitric oxide
Address for reprint requests and other correspondence: C. A. DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354 UCB, Boulder, CO 80309 (e-mail: desouzac{at}colorado.edu )</description><identifier>ISSN: 0363-6135</identifier><identifier>EISSN: 1522-1539</identifier><identifier>DOI: 10.1152/ajpheart.01281.2007</identifier><identifier>PMID: 18281379</identifier><identifier>CODEN: AJPPDI</identifier><language>eng</language><publisher>United States: American Physiological Society</publisher><subject><![CDATA[Acetylcholine - administration & dosage ; Adult ; Aged ; Blood vessels ; Body Mass Index ; Bradykinin - administration & dosage ; Cells ; Dose-Response Relationship, Drug ; Endothelium, Vascular - drug effects ; Endothelium, Vascular - enzymology ; Endothelium, Vascular - metabolism ; Endothelium, Vascular - physiopathology ; Enzyme Inhibitors - administration & dosage ; Female ; Forearm - blood supply ; Humans ; Infusions, Intravenous ; Isoproterenol - administration & dosage ; Male ; Methacholine Chloride - administration & dosage ; Middle Aged ; Muscarinic Agonists - administration & dosage ; NG-Nitroarginine Methyl Ester - administration & dosage ; Nitric oxide ; Nitric Oxide - metabolism ; Nitric Oxide Synthase - antagonists & inhibitors ; Nitric Oxide Synthase - metabolism ; Nitroprusside - administration & dosage ; Obesity ; Obesity - metabolism ; Obesity - physiopathology ; Regional Blood Flow - drug effects ; Signal Transduction - drug effects ; Studies ; Substance P - administration & dosage ; Vasodilation - drug effects ; Vasodilator Agents - administration & dosage]]></subject><ispartof>American journal of physiology. Heart and circulatory physiology, 2008-04, Vol.294 (4), p.H1685-H1692</ispartof><rights>Copyright American Physiological Society Apr 2008</rights><rights>Copyright © 2008 the American Physiological Society 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</citedby><cites>FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,781,785,886,3040,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18281379$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Van Guilder, Gary P</creatorcontrib><creatorcontrib>Stauffer, Brian L</creatorcontrib><creatorcontrib>Greiner, Jared J</creatorcontrib><creatorcontrib>DeSouza, Christopher A</creatorcontrib><title>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</title><title>American journal of physiology. Heart and circulatory physiology</title><addtitle>Am J Physiol Heart Circ Physiol</addtitle><description>1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado
Submitted 1 November 2007
; accepted in final form 13 February 2008
Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO.
cell surface receptors; intracellular signaling pathways; nitric oxide
Address for reprint requests and other correspondence: C. A. DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354 UCB, Boulder, CO 80309 (e-mail: desouzac{at}colorado.edu )</description><subject>Acetylcholine - administration & dosage</subject><subject>Adult</subject><subject>Aged</subject><subject>Blood vessels</subject><subject>Body Mass Index</subject><subject>Bradykinin - administration & dosage</subject><subject>Cells</subject><subject>Dose-Response Relationship, Drug</subject><subject>Endothelium, Vascular - drug effects</subject><subject>Endothelium, Vascular - enzymology</subject><subject>Endothelium, Vascular - metabolism</subject><subject>Endothelium, Vascular - physiopathology</subject><subject>Enzyme Inhibitors - administration & dosage</subject><subject>Female</subject><subject>Forearm - blood supply</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Isoproterenol - administration & dosage</subject><subject>Male</subject><subject>Methacholine Chloride - administration & dosage</subject><subject>Middle Aged</subject><subject>Muscarinic Agonists - administration & dosage</subject><subject>NG-Nitroarginine Methyl Ester - administration & dosage</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide Synthase - antagonists & inhibitors</subject><subject>Nitric Oxide Synthase - metabolism</subject><subject>Nitroprusside - administration & dosage</subject><subject>Obesity</subject><subject>Obesity - metabolism</subject><subject>Obesity - physiopathology</subject><subject>Regional Blood Flow - drug effects</subject><subject>Signal Transduction - drug effects</subject><subject>Studies</subject><subject>Substance P - administration & dosage</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - administration & dosage</subject><issn>0363-6135</issn><issn>1522-1539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UV2LEzEUDaK4dfUXCBJ8n24-JukMgiCL6y4s-LI-h3Ry00mZScYk07VP_nVTW-v64FMI5-Oeew9CbylZUirYld5OPeiYl4Syhi4ZIatnaFEQVlHB2-doQbjklaRcXKBXKW0JIWIl-Ut0QZui4Kt2gX7ejZN2EQwGb0LuYXDzWBmYyhd8xjudgnGDzi547DwOO4iP4DZ9xtobHNaQAGszDxn386h9wi5hHzIe3Ohysc0Bj3PqdHTedThCB1MOEetN8C7l9Bq9sHpI8Ob0XqJvN58frm-r-69f7q4_3Vdd2SdXYCwzFARIsK22TddoyVZMMGE7a0hTkHotCLcW6q5uNDGSWIBG0rWw0lB-iT4efad5PYLpym5RD2qKbtRxr4J26l_Eu15twk5xWUxoXQzenwxi-D5Dymob5uhLZsVYK0UryGEKP5K6GFKKYM8DKFGH0tSf0tTv0tShtKJ69zTbX82ppUL4cCT05fCPpS019fvkwhA2e3UzD8MD_Mhna9bWqla3VDZCTcYW9dX_1ec8T1T8F4n6wV4</recordid><startdate>20080401</startdate><enddate>20080401</enddate><creator>Van Guilder, Gary P</creator><creator>Stauffer, Brian L</creator><creator>Greiner, Jared J</creator><creator>DeSouza, Christopher A</creator><general>American Physiological Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TS</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20080401</creationdate><title>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</title><author>Van Guilder, Gary P ; Stauffer, Brian L ; Greiner, Jared J ; DeSouza, Christopher A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c522t-edf2d1e5e6ef9af8c8a6272525fcfd08e5e4b503ffe4c48a0d60fee861b5f6d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acetylcholine - administration & dosage</topic><topic>Adult</topic><topic>Aged</topic><topic>Blood vessels</topic><topic>Body Mass Index</topic><topic>Bradykinin - administration & dosage</topic><topic>Cells</topic><topic>Dose-Response Relationship, Drug</topic><topic>Endothelium, Vascular - drug effects</topic><topic>Endothelium, Vascular - enzymology</topic><topic>Endothelium, Vascular - metabolism</topic><topic>Endothelium, Vascular - physiopathology</topic><topic>Enzyme Inhibitors - administration & dosage</topic><topic>Female</topic><topic>Forearm - blood supply</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Isoproterenol - administration & dosage</topic><topic>Male</topic><topic>Methacholine Chloride - administration & dosage</topic><topic>Middle Aged</topic><topic>Muscarinic Agonists - administration & dosage</topic><topic>NG-Nitroarginine Methyl Ester - administration & dosage</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide Synthase - antagonists & inhibitors</topic><topic>Nitric Oxide Synthase - metabolism</topic><topic>Nitroprusside - administration & dosage</topic><topic>Obesity</topic><topic>Obesity - metabolism</topic><topic>Obesity - physiopathology</topic><topic>Regional Blood Flow - drug effects</topic><topic>Signal Transduction - drug effects</topic><topic>Studies</topic><topic>Substance P - administration & dosage</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Van Guilder, Gary P</creatorcontrib><creatorcontrib>Stauffer, Brian L</creatorcontrib><creatorcontrib>Greiner, Jared J</creatorcontrib><creatorcontrib>DeSouza, Christopher A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Physical Education Index</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of physiology. Heart and circulatory physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Van Guilder, Gary P</au><au>Stauffer, Brian L</au><au>Greiner, Jared J</au><au>DeSouza, Christopher A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists</atitle><jtitle>American journal of physiology. Heart and circulatory physiology</jtitle><addtitle>Am J Physiol Heart Circ Physiol</addtitle><date>2008-04-01</date><risdate>2008</risdate><volume>294</volume><issue>4</issue><spage>H1685</spage><epage>H1692</epage><pages>H1685-H1692</pages><issn>0363-6135</issn><eissn>1522-1539</eissn><coden>AJPPDI</coden><abstract>1 Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder; 2 Department of Medicine, University of Colorado Health Sciences Center, and 3 Division of Cardiology, Department of Medicine, Denver Health and Hospital Authority, Denver, Colorado
Submitted 1 November 2007
; accepted in final form 13 February 2008
Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however, yields limited, and potentially misleading, information regarding endothelial vasodilator capacity. The aims of this study were to determine 1 ) whether the overweight/obesity-related reduction in endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2 ) whether the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight (54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m 2 ) and 44 overweight/obese (54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m 2 ) subjects. Forearm blood flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the endothelial NO synthase inhibitor N G -monomethyl- L -arginine, methacholine, bradykinin, substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge plethysmography. FBF responses to each endothelial agonist were significantly blunted in the overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4 ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs. 82 ± 6 ml/100 ml tissue) were 30%-40% lower in the overweight/obese than normal-weight adults. N G -monomethyl- L -arginine significantly reduced the FBF response to acetylcholine to the same extent in both groups. There were no differences between the groups in the FBF responses to sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent vasodilation is universally impaired with overweight/obesity. Moreover, this impairment appears to be independent of NO.
cell surface receptors; intracellular signaling pathways; nitric oxide
Address for reprint requests and other correspondence: C. A. DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354 UCB, Boulder, CO 80309 (e-mail: desouzac{at}colorado.edu )</abstract><cop>United States</cop><pub>American Physiological Society</pub><pmid>18281379</pmid><doi>10.1152/ajpheart.01281.2007</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0363-6135 |
ispartof | American journal of physiology. Heart and circulatory physiology, 2008-04, Vol.294 (4), p.H1685-H1692 |
issn | 0363-6135 1522-1539 |
language | eng |
recordid | cdi_highwire_physiology_ajpheart_294_4_H1685 |
source | MEDLINE; American Physiological Society; Alma/SFX Local Collection; EZB Electronic Journals Library |
subjects | Acetylcholine - administration & dosage Adult Aged Blood vessels Body Mass Index Bradykinin - administration & dosage Cells Dose-Response Relationship, Drug Endothelium, Vascular - drug effects Endothelium, Vascular - enzymology Endothelium, Vascular - metabolism Endothelium, Vascular - physiopathology Enzyme Inhibitors - administration & dosage Female Forearm - blood supply Humans Infusions, Intravenous Isoproterenol - administration & dosage Male Methacholine Chloride - administration & dosage Middle Aged Muscarinic Agonists - administration & dosage NG-Nitroarginine Methyl Ester - administration & dosage Nitric oxide Nitric Oxide - metabolism Nitric Oxide Synthase - antagonists & inhibitors Nitric Oxide Synthase - metabolism Nitroprusside - administration & dosage Obesity Obesity - metabolism Obesity - physiopathology Regional Blood Flow - drug effects Signal Transduction - drug effects Studies Substance P - administration & dosage Vasodilation - drug effects Vasodilator Agents - administration & dosage |
title | Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T20%3A43%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impaired%20endothelium-dependent%20vasodilation%20in%20overweight%20and%20obese%20adult%20humans%20is%20not%20limited%20to%20muscarinic%20receptor%20agonists&rft.jtitle=American%20journal%20of%20physiology.%20Heart%20and%20circulatory%20physiology&rft.au=Van%20Guilder,%20Gary%20P&rft.date=2008-04-01&rft.volume=294&rft.issue=4&rft.spage=H1685&rft.epage=H1692&rft.pages=H1685-H1692&rft.issn=0363-6135&rft.eissn=1522-1539&rft.coden=AJPPDI&rft_id=info:doi/10.1152/ajpheart.01281.2007&rft_dat=%3Cproquest_highw%3E1460409201%3C/proquest_highw%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=229659501&rft_id=info:pmid/18281379&rfr_iscdi=true |